Repositioning of Metformin: Anticancer Agent for Hypoxic Neuroblastoma Cells

Surer S. I., Toksoz F., Bayrak S., Meco H. E., Sever T., Başbınar Y., ...Daha Fazla

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, cilt.4, sa.3, ss.384-390, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.30621/jbachs.2020.1373
  • Dergi Adı: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.384-390
  • Anahtar Kelimeler: neuroblastoma, metformin, hypoxia, HIF-1 alpha, VEGF-A, PDK-1, ANGIOGENESIS, METABOLISM, CANCER
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives:Neuroblastoma is an extracranial solid tumor of early childhood that has a hypoxic environment. VEGF and HIFs molecules play a role in adaptation to this microenvironment. Hypoxic microenvironment leads to poor prognosis and inadequate treatment of neuroblastoma. Metformin has been shown to inhibit tumor growth, might be a potential chemotherapeutic agent. The anti-cancer activity of Metformin on SH-SY5Y cells are not fully elucidated. The aim of this study is to determine the anti-cancer effect of Metformin on SH-SY5Y cells and to elucidate its molecular action mechanism in hypoxia/normoxia.